Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Receivables (2022 - 2025)

Atara Biotherapeutics' Change in Receivables history spans 4 years, with the latest figure at -$660000.0 for Q4 2025.

  • For Q4 2025, Change in Receivables fell 548.98% year-over-year to -$660000.0; the TTM value through Dec 2025 reached -$229000.0, up 99.3%, while the annual FY2025 figure was -$229000.0, 99.3% up from the prior year.
  • Change in Receivables reached -$660000.0 in Q4 2025 per ATRA's latest filing, down from $1.9 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $40.0 million in Q4 2022 to a low of -$39.8 million in Q1 2023.
  • Average Change in Receivables over 4 years is $16687.5, with a median of -$174500.0 recorded in 2022.
  • Peak YoY movement for Change in Receivables: soared 454.84% in 2023, then crashed 30474.55% in 2024.
  • A 4-year view of Change in Receivables shows it stood at $40.0 million in 2022, then fell by 15.08% to $33.9 million in 2023, then crashed by 99.57% to $147000.0 in 2024, then plummeted by 548.98% to -$660000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Change in Receivables are -$660000.0 (Q4 2025), $1.9 million (Q3 2025), and -$8.9 million (Q2 2025).